Lumos Clinical Research Center | San Jose, CA

Research site

(Unclaimed)

Location

2516 Samaritan Drive Suite B, San Jose, California, United States of America

Site insights

Top conditions

Top treatments

BHV-7000

Atogepant

Troriluzole

Cariprazine

BTRX-335140

Ubrogepant

NMRA-335140

Troriluzule

Psilocybin

Aticaprant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

12 of 13 total trials

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (VENTURA-7)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Active, not recruiting

Anhedonia

Depressive Disorder, Major

Drug: Aticaprant

Other: Placebo

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (3112 Ped BPD)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (ATO EM PEDS)

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling

Episodic Migraine

Drug: Placebo-Matching Atogepant

Drug: Atogepant

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling

Obsessive-Compulsive Disorder

Drug: Placebo

Drug: Troriluzole

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Active, not recruiting

Obsessive-Compulsive Disorder

Drug: Troriluzole

Drug: Placebo

Locations recently updated

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling

Major Depressive Disorder

Drug: BHV-7000

Drug: Placebo

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling

Treatment Resistant Depression

Drug: Psilocybin

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine (Kaleidoscope)

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only

Migraine Prophylaxis

Drug: Atogepant

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only

Major Depressive Disorder

Drug: BHV-7000

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant